Ondine Biomedical Inc.
OBIMF
$0.11
-$0.02-15.39%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 3.54% | 1.43% | 39.85% | 41.36% | 12.40% |
| Total Depreciation and Amortization | -8.55% | -6.57% | 10.33% | 7.57% | 21.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -28.68% | -27.06% | -117.39% | -116.90% | -41.47% |
| Change in Net Operating Assets | 101.69% | 101.73% | -20.64% | -22.63% | -15.63% |
| Cash from Operations | 14.92% | 13.06% | 31.25% | 32.97% | 7.47% |
| Capital Expenditure | 94.29% | 94.25% | 92.90% | 93.17% | 38.52% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 94.29% | 94.25% | 92.90% | 93.17% | 38.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -6.16% | -6.16% | -89.47% | -89.47% | -52.90% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,560.00% | 2,612.82% | 3,596.67% | 3,508.70% | -24.41% |
| Foreign Exchange rate Adjustments | 131.71% | 132.41% | -91.61% | -91.82% | -2.38% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.02% | 79.58% | 81.12% | 81.60% | 7.70% |
